These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 34078115)

  • 1. Impact of Interferons and Biological Drug Inhibitors of IL-2 and IL-6 on Small-Molecule Drug Metabolism Through the Cytochrome P450 System.
    White CM; Sicignano DJ; Smith K
    Ann Pharmacother; 2022 Feb; 56(2):170-180. PubMed ID: 34078115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation Suppresses Patients' Ability to Metabolize Cytochrome P450 Substrate Drugs.
    White CM
    Ann Pharmacother; 2022 Jul; 56(7):809-819. PubMed ID: 34590872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6.
    Jiang X; Zhuang Y; Xu Z; Wang W; Zhou H
    AAPS J; 2016 May; 18(3):767-76. PubMed ID: 26961818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach.
    Zhuang Y; de Vries DE; Xu Z; Marciniak SJ; Chen D; Leon F; Davis HM; Zhou H
    J Clin Pharmacol; 2015 Dec; 55(12):1386-94. PubMed ID: 26054042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
    Darwish M; Kirby M; Robertson P; Hellriegel ET
    Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations.
    Machavaram KK; Endo-Tsukude C; Terao K; Gill KL; Hatley OJ; Gardner I; Parrott N; Ducray PS
    AAPS J; 2019 Mar; 21(3):42. PubMed ID: 30887238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer.
    Turner PK; Hall SD; Chapman SC; Rehmel JL; Royalty JE; Guo Y; Kulanthaivel P
    Drug Metab Dispos; 2020 Sep; 48(9):796-803. PubMed ID: 32581049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-6 and cytochrome-P450, reason for concern?
    Kim S; Östör AJ; Nisar MK
    Rheumatol Int; 2012 Sep; 32(9):2601-4. PubMed ID: 22451032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
    Chainuvati S; Nafziger AN; Leeder JS; Gaedigk A; Kearns GL; Sellers E; Zhang Y; Kashuba AD; Rowland E; Bertino JS
    Clin Pharmacol Ther; 2003 Nov; 74(5):437-47. PubMed ID: 14586384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a method to determine cytochrome P450 1A2, 2C9, 2D6 and 3A4 activity sheep hepatic microsomes.
    McBride GM; Soo JY; Varcoe T; Morrison JL; Wiese MD
    J Pharmacol Toxicol Methods; 2020; 106():106934. PubMed ID: 33080390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis.
    Jenkins J; Williams D; Deng Y; Collins DA; Kitchen VS
    Eur J Clin Pharmacol; 2010 Jan; 66(1):67-76. PubMed ID: 19756558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults.
    Armani S; Ting L; Sauter N; Darstein C; Tripathi AP; Wang L; Zhu B; Gu H; Chun DY; Einolf HJ; Kulkarni S
    Clin Drug Investig; 2017 May; 37(5):465-472. PubMed ID: 28155129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Short-Term Fasting on Systemic Cytochrome P450-Mediated Drug Metabolism in Healthy Subjects: A Randomized, Controlled, Crossover Study Using a Cocktail Approach.
    Lammers LA; Achterbergh R; van Schaik RHN; Romijn JA; Mathôt RAA
    Clin Pharmacokinet; 2017 Oct; 56(10):1231-1244. PubMed ID: 28229374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
    Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
    Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
    Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
    Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of kale ingestion on metabolism by cytochrome P450 enzymes in rats.
    Yamasaki I; Yamada M; Uotsu N; Teramoto S; Takayanagi R; Yamada Y
    Biomed Res; 2012; 33(4):235-42. PubMed ID: 22975634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.
    Frye RF; Branch RA
    Br J Clin Pharmacol; 2002 Feb; 53(2):155-62. PubMed ID: 11851639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of commercial Rhodiola rosea on CYP enzyme activity in humans.
    Thu OK; Spigset O; Nilsen OG; Hellum B
    Eur J Clin Pharmacol; 2016 Mar; 72(3):295-300. PubMed ID: 26613955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
    Wen X; Wang JS; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.